Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Patterns in detection of recurrence among patients treated for breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. DBCG Kvalitetsdatabase for Brystkræft – resumé af årsrapport 2020

    Research output: Contribution to journalJournal articleCommunication

  2. A careful reassessment of anthracycline use in curable breast cancer

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.

METHODS: From a DBCG cohort, 140 consecutive patients were treated with epirubicin between May 1997 and November 2016. After patient informed consent, mRNA was isolated from archival formalin-fixed paraffin-embedded primary breast tumor tissue and analyzed using Affymetrix arrays. Using time to progression (TTP) as primary endpoint, the efficacy of epirubicin was analyzed according to DRP combined with clinicopathological data collected retrospectively from patients' medical records. Statistical analysis was done using Cox proportional hazards model stratified by treatment line.

RESULTS: Median TTP was 9.3 months. The DRP was significantly associated to TTP (P = 0.03). The hazard ratio for DRP scores differing by 50 percentage points was 0.55 (95% CI -0.93, one-sided). A 75% DRP was associated with a median TTP of 13 months compared to 7 months following a 25% DRP. Multivariate analysis showed that DRP was independent of age and number of metastases.

CONCLUSION: The current study prospectively validates the predictive capability of DRP regarding epirubicin previously shown retrospectively allowing the patients predicted to be poor responders to choose more effective alternatives. Randomized prospective studies are needed to demonstrate if such an approach will lead to increased overall survival.

Original languageEnglish
JournalBreast Cancer Research and Treatment
Volume172
Issue number2
Pages (from-to)391-400
ISSN0167-6806
DOIs
Publication statusPublished - 2018

ID: 55423734